Linked Life Data

18063543

Source:http://linkedlifedata.com/resource/pubmed/id/18063543

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2007-12-7
pubmed:abstractText
Immunomodulating agents such as thalidomide and its newly emerged derivative, lenalidomide, are becoming increasingly popular in the treatment of multiple myeloma because of their ability to combat drug resistance. Clinical trials suggest that thalidomide and lenalidomide are effective in all stages of multiple myeloma treatment-new diagnoses, stem cell transplantations, maintenance therapy, and relapsed or refractory disease. The drugs are most efficacious when combined with additional chemotherapeutic agents and/or corticosteroids. However, deep vein thrombosis and other thromboembolic events are associated with the treatment regimens. Oncology nurses must understand the pharmacologic properties of the drugs and the potentially life-threatening complications associated with them. To provide the highest standard of care, oncology nurses must play a vital role in the prevention, diagnosis, and management of thromboembolic events through awareness of the clinical problem, assessment tools, and thromboembolic prophylactic regimens.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
N
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1092-1095
pubmed:author
pubmed:issnType
Print
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
847-51
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Multiple myeloma and treatment-related thromboembolism: oncology nurses' role in prevention, assessment, and diagnosis.
pubmed:affiliation
University of Pennsylvania Abramson Cancer Center, Philadelphia, USA. kathleen.wiley@uphs.upenn.edu
pubmed:publicationType
Journal Article, Review